AI assistant
ABBOTT LABORATORIES — Director's Dealing 2020
Oct 5, 2020
29777_dirs_2020-10-05_b4d9dbdf-497e-4707-90c1-0937cd76d1a3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2020-10-01
Reporting Person: Ahlberg Gregory A (Senior Vice President)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-10-01 | Common shares without par value | A | 1490 | — | Acquired | 8016 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-10-01 | Option (right to buy) | $109.36 | A | 9084 | Acquired | 2030-09-30 | Common Shares (9084) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common shares without par value | 10596 | Indirect |
Footnotes
F1: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
F2: Balance in the Abbott Laboratories Stock Retirement Trust as of October 1, 2020.
F3: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 3,028 on each of October 1, 2021, October 1, 2022 and October 1, 2023.